Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

We previously reported that our novel compound 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (VN/124-1) is a potent 17α-hydroxylase/17,20-lyase (CYP17) inhibitor/antiandrogen and strongly inhibits the formation and proliferation of human prostate cancer LAPC4 tumor xenografts in severe combined immunodeficient mice. In this study, we report that VN/124-1 and other novel CYP17 inhibitors also cause down-regulation of androgen receptor (AR) protein expression in vitro and in vivo. This mechanism of action seems to contribute to their antitumor efficacy. We compared the in vivo antitumor efficacy of VN/124-1 with that of castration and a clinically used antiandrogen, Casodex, and show that VN/124-1 is more potent than castration in the LAPC4 xenograft model. Treatment with VN/124-1 (0.13 mmol/kg twice daily) was also very effective in preventing the formation of LAPC4 tumors (6.94 versus 2410.28 mm3 in control group). VN/124-1 (0.13 mmol/kg twice daily) and VN/124-1 (0.13 mmol/kg twice daily) + castration induced regression of LAPC4 tumor xenografts by 26.55% and 60.67%, respectively. Treatments with Casodex (0.13 mmol/kg twice daily) or castration caused significant tumor suppression compared with control. Furthermore, treatment with VN/124-1 caused marked down-regulation of AR protein expression, in contrast to treatments with Casodex or castration that caused significant up-regulation of AR protein expression. The results suggest that VN/124-1 acts by several mechanisms (CYP17 inhibition, competitive inhibition, and down-regulation of the AR). These actions contribute to inhibition of the formation of LAPC4 tumors and cause regression of growth of established tumors. VN/124-1 is more efficacious than castration in the LAPC4 xenograft model, suggesting that the compound has potential for the treatment of prostate cancer. [Mol Cancer Ther 2008;7(8):2348–57]

[1]  Zhiwei Wang,et al.  Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. , 2006, Cancer research.

[2]  Lin Qiu,et al.  Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. , 2005, Cancer research.

[3]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[4]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[5]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[6]  K. Takahashi,et al.  Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer , 2007, Prostate Cancer and Prostatic Diseases.

[7]  J T Arnold,et al.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. , 2002, Endocrine-related cancer.

[8]  J. Norris,et al.  Mechanism of androgen-receptor augmentation. Analysis of receptor synthesis and degradation by the density-shift technique. , 1985, The Journal of biological chemistry.

[9]  E. Small,et al.  Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. , 1997, The Journal of urology.

[10]  Hong-Bin Fang,et al.  Small‐Sample Inference for Incomplete Longitudinal Data with Truncation and Censoring in Tumor Xenograft Models , 2002, Biometrics.

[11]  D. Horsfall,et al.  Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3 , 1995, Steroids.

[12]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[13]  J. Trachtenberg,et al.  Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. , 1983, The Journal of urology.

[14]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[15]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Brooks,et al.  A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells , 2007, Nucleic acids research.

[18]  S. Yeh,et al.  From estrogen to androgen receptor: a new pathway for sex hormones in prostate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Hall.  Cytochrome P-450 C21scc: One enzyme with two actions: Hydroxylase and lyase , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  G. Prendergast.  Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .

[21]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[22]  D. Grigoryev,et al.  Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. , 2000, Cancer research.

[23]  Hong-Chiang Chang,et al.  Differential induction of androgen receptor transactivation by different androgen receptor coativators in human prostate cancer DU 145 cells , 1999, Endocrine.

[24]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[25]  Chawnshang Chang,et al.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.

[26]  V. Njar,et al.  Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[28]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[29]  T. Jaworski.  Degradation and beyond: Control of androgen receptor activity by the proteasome system , 2006, Cellular & Molecular Biology Letters.

[30]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[31]  A. Belldegrun,et al.  Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer , 2005, BJU international.

[32]  A. Z. D. Ziel-van der Made,et al.  Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer , 2002, International journal of cancer.

[33]  R. Bernhardt,et al.  CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. , 2006, Pharmacology & therapeutics.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  Pankaj Chopra,et al.  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. , 2005, Journal of medicinal chemistry.

[36]  Katsuya Kato,et al.  Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-Hydroxylase-C17,20-lyase (P45017α) : Potential agents for the treatment of prostate cancer , 1998 .

[37]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[38]  G. Wilding,et al.  Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. , 2003, Molecular cancer therapeutics.

[39]  N. Bruchovsky.  The Conversion of Testosterone to 5 ~-Androstan-17 ~-ol-3-one by Rat Prostate in Viwo and in Vitro * , 2003 .

[40]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[41]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[42]  Tao Zhang,et al.  Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. , 2006, The American journal of pathology.

[43]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[44]  F. Leroux,et al.  Inhibition of p450 17 as a new strategy for the treatment of prostate cancer. , 2005, Current medicinal chemistry.

[45]  G. Klus,et al.  Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. , 1996, Cancer research.

[46]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.